Skip to main content
. 2012 Sep 18;21(1):91–100. doi: 10.1038/mt.2012.184

Figure 5.

Figure 5

CpG conjugation improves the antitumor effect of Cetuximab. (a) Approximately 1 × 104 TUBO-EGFR cells were plated in 96-well plate and incubated with 10, 3, or 0.3 µg/ml Cetuximab or anti-neu antibodies. Cell viability was measured by an MTT assay at 24, 36, and 72 hours after incubation. Cell growth rate was normalized to control cell growth. (b) Wild type (Wt) BALB/c mice (n = 5/group) were injected subcutaneously with 5 × 105 TUBO-EGFR and treated with 40 µg of human Ig (hIg), Cetuximab, Cetuximab-CpG, or 10 µg of CpG on days 14, 18, and 22. Tumor growth was measured and compared twice a week. *P < 0.05 compared to Cetuximab-treated Wt mice. One of three representative experiments is shown. (c) Wt BALB/c mice (n = 5/group) were injected subcutaneously with 5 × 105 TUBO-EGFR and treated with 40 µg of hIg or Cetuximab-CpG on days 14, 18, and 22. A CD8-depleting antibody (200 µg/mouse) was administered on days 14, 21, and 28. Tumor growth was measured and compared twice a week. *P < 0.05, compared to Cetuximab-CpG-treated Wt mice. One of three representative experiments is shown. (d) Wt BALB/c mice or cured Cetuximab-CpG treated mice (n = 5/group) were injected subcutaneously with 2 × 106 TUBO-EGFR, and the growth of tumor was measured and compared twice a week. *P < 0.05, compared to naive Wt mice. One of three representative experiments is shown. EGFR, epidermal growth factor receptor.